Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer
Open Access
- 12 June 2024
- journal article
- research article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 32 (3) , 200826
Abstract
No abstract availableKeywords
Funding Information
- Santé
- Fondation du cancer du sein du Québec
- Université de Montréal
- Ovarian Cancer Canada
- Institut Du Cancer de Montréal (51358)
- Institut Du Cancer de Montréal (51378)
This publication has 53 references indexed in Scilit:
- Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapyJournal of Medical Virology, 2023
- Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A ReviewClinical Pharmacokinetics, 2023
- The role of cancer metabolism in defining the success of oncolytic viro-immunotherapyCytokine & Growth Factor Reviews, 2020
- The pros and cons of interferons for oncolytic virotherapyCytokine & Growth Factor Reviews, 2020
- MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer CellsMolecular Therapy-Oncolytics, 2020
- Oncogenic Signaling Pathways in The Cancer Genome AtlasCell, 2018
- Programmable insect cell carriers for systemic delivery of integrated cancer biotherapyJournal of Controlled Release, 2015
- DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical BiologyChemistry & Biology, 2013
- Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: Role of type I interferon signalingVirology, 2013
- Effect of Transforming Viruses on Molecular Mechanisms Associated With CancerJournal of Cellular Physiology, 2008